Clinical survival analysis suggests that the poor prognosis of patients with NSCLC is correlated with high expression of S1PR1, S1PR2, S1PR3, and S1PR5, suggesting that S1PR targeting through Fingolimod might be relevant in n NSCLC models. This evidence concerns the gene S1PR2 and non-small cell lung carcinoma.